四价重组流感血凝素疫苗在动物模型中诱导强效保护性免疫应答
研究开发了含标准剂量重组血凝素蛋白(每株15μg)和油包水佐剂CD-A的四价季节性流感疫苗SCVC101-S,在小鼠、大鼠和恒河猴中诱导的体液和细胞免疫应答超过市售疫苗,单次注射即可在恒河猴中诱导强免疫应答,并诱导针对异源毒株的交叉保护,临床前显示安全有效,需进一步开展人体临床试验。
要点
- SCVC101-S含标准剂量重组血凝素蛋白(每株15μg)和油包水佐剂CD-A。
- 在小鼠、大鼠和恒河猴中诱导的体液和细胞免疫应答超过市售疫苗。
- 恒河猴单次注射即诱导强免疫应答,并诱导针对异源毒株的交叉保护。
核心结论
- SCVC101-S在临床前研究中显示安全有效,需进一步开展人体临床试验。
- SCVC101-S有望成为季节性流感疫苗的有价值补充,尤其对老年人群。
研究设计与样本
- 临床前研究,在小鼠、大鼠和恒河猴中评估SCVC101-S的免疫原性和保护效果。
主要发现
- SCVC101-S在小鼠、大鼠和恒河猴中诱导的体液和细胞免疫应答超过市售疫苗。
- 恒河猴单次注射SCVC101-S即可诱导强免疫应答。
- SCVC101-S诱导针对异源毒株的交叉保护免疫应答。
关键数值与推荐
- SCVC101-S含标准剂量蛋白(每株病毒15μg重组血凝素)和油包水佐剂CD-A。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, influenza poses a substantial threat to public health, serving as a major contributor to both morbidity and mortality. The current vaccines for seasonal influenza are not optimal. A novel recombinant hemagglutinin (rHA) protein-based quadrivalent seasonal influenza vaccine, SCVC101, has been developed. SCVC101-S contains standard dose protein (15μg of rHA per virus strain) and an oil-in-water adjuvant, CD-A, which enhances the immunogenicity and cross-protection of the vaccine. Preclinical studies in mice, rats, and rhesus macaques demonstrate that SCVC101-S induces robust humoral and cellular immune responses, surpassing those induced by commercially available vaccines. Notably, a single injection with SCVC101-S can induce a strong immune response in macaques, suggesting the potential for a standard-dose vaccination with a recombinant protein influenza vaccine. Furthermore, SCVC101-S induces cross-protection immune responses against heterologous viral strains, indicating broader protection than current vaccines. In conclusion, SCVC101-S has demonstrated safety and efficacy in preclinical settings and warrants further investigation in human clinical trials. Its potential as a valuable addition to the vaccines against seasonal influenza, particularly for the elderly population, is promising.
引用
- Feng J, Du Y, Chen L, et al. A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models. Vaccine. 2024. PMID: 38834431. doi:10.1016/j.vaccine.2024.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。